deltatrials
Active Not Recruiting PHASE1 INTERVENTIONAL 1-arm NCT02498912

Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors

A Phase I Clinical Trial of Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Conditions Solid Tumors
Interventions Cyclophosphamide Fludarabine IP Catheter Insertion Infusion of 4H11-28z/fIL-12/EGFRt+ Genetically-modified T cells Production of Genetically-modified T cells
Updated 19 times since 2017 Last updated: Jul 30, 2025 Started: Aug 31, 2015 Primary completion: Aug 31, 2026 Completion: Aug 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02498912, this PHASE1 trial focuses on Solid Tumors and remains ongoing. Sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, it has been updated 19 times since 2015, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~Feb 2018 · 11 months · monthly snapshot~Feb 2018 – ~Jun 2018 · 4 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Nov 2018 · 3 months · monthly snapshot~Nov 2018 – ~May 2019 · 6 months · monthly snapshot~May 2019 – ~May 2020 · 12 months · monthly snapshot~May 2020 – ~Jan 2021 · 8 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Mar 2022 · 12 months · monthly snapshot~Mar 2022 – ~Sep 2022 · 6 months · monthly snapshot~Sep 2022 – ~Oct 2023 · 13 months · monthly snapshot~Oct 2023 – ~Nov 2023 · 31 days · monthly snapshot~Nov 2023 – ~Jul 2024 · 8 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Aug 2025 · 11 months · monthly snapshot~Aug 2025 – present · 13 months · monthly snapshot

Change History

19 versions recorded

  1. Aug 2025 — Present [monthly]

    Active Not Recruiting PHASE1

  2. Sep 2024 — Aug 2025 [monthly]

    Active Not Recruiting PHASE1

  3. Aug 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1

  4. Jul 2024 — Aug 2024 [monthly]

    Active Not Recruiting PHASE1

  5. Nov 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1

▶ Show 14 earlier versions

  1. Oct 2023 — Nov 2023 [monthly]

    Active Not Recruiting PHASE1

  2. Sep 2022 — Oct 2023 [monthly]

    Active Not Recruiting PHASE1

  3. Mar 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE1

  4. Mar 2021 — Mar 2022 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  5. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE1

  6. May 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

  7. May 2019 — May 2020 [monthly]

    Recruiting PHASE1

  8. Nov 2018 — May 2019 [monthly]

    Recruiting PHASE1

  9. Aug 2018 — Nov 2018 [monthly]

    Recruiting PHASE1

  10. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE1

  11. Feb 2018 — Jun 2018 [monthly]

    Recruiting PHASE1

  12. Mar 2017 — Feb 2018 [monthly]

    Recruiting PHASE1

  13. Feb 2017 — Mar 2017 [monthly]

    Recruiting PHASE1

  14. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1

    First recorded

Aug 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
  • Memorial Sloan Kettering Cancer Center
  • Stanford University
Data source: Memorial Sloan Kettering Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations